{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:20:28Z","timestamp":1793614828435,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":9092,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1987,3,4]]},"abstract":"<jats:p>Intravenous immune globulin (IV\u2010IgG) is approved for use in substitution therapy of immunodeficiency syndromes and treatment of idiopathic thrombocytopenic purpura (ITP). The initial dose for substitution therapy is 0.2 g\/kg body weight repeated monthly. If necessary, the dose may be increased to 0.3 g\/kg and the frequency to every 2\u20133 weeks. The approved dosage for ITP is 0.4 g\/kg daily for 2 to 5 consecutive days. Repeat doses of 0.4 g\/kg have been used as maintenance therapy. The initial infusions of IgG to immunodeficient patients who have not been treated during the previous 8 weeks or never treated at all should proceed with caution. These patients are at risk of potentially serious complement\u2010mediated adverse reactions. Adverse reactions due to IgG administration are less frequent and less severe for patients with ITP. Currently available preparations are contraindicated in patients with a selective IgA deficiency and detectable IgA antibodies.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1987.tb03510.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T12:55:23Z","timestamp":1450270523000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intravenous Immune Globulin: Dosage and Administration"],"prefix":"10.1002","volume":"7","author":[{"given":"Cindy J.","family":"Wordell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0308-2261(18)30033-X","article-title":"Clinical use of immunoglobulins","volume":"13","author":"McClelland DBL","year":"1984","journal-title":"Clin Haematol"},{"key":"e_1_2_1_3_2","first-page":"123","volume-title":"Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy","author":"Romer J","year":"1981"},{"key":"e_1_2_1_4_2","volume-title":"Product literature","author":"Sandoz Pharmaceuticals Corporation.","year":"1986"},{"key":"e_1_2_1_5_2","volume-title":"Gamimune promotional literature","author":"Cutter Blologlcals","year":"1986"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198207223070420"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91504-6"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90701-3"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90729-3"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92451-1"},{"key":"e_1_2_1_11_2","volume-title":"White cell manual","author":"Boggs DR","year":"1975"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90320-6"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-4-435"},{"key":"e_1_2_1_14_2","first-page":"283","volume-title":"Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy","author":"Cunningham\u2010Rundles C","year":"1981"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00918362"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00918363"},{"key":"e_1_2_1_17_2","first-page":"81","article-title":"High\u2010dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood","volume":"46","author":"Imbach P","year":"1981","journal-title":"Helv Paediatr Acta"},{"key":"e_1_2_1_18_2","first-page":"206","article-title":"Immune globulin in the treatment of autoimmune thrombocytopenic purpura","volume":"4","author":"Wordell CJ","year":"1985","journal-title":"Clin Pharm"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.2.480.480"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90319-X"},{"key":"e_1_2_1_21_2","first-page":"447","volume-title":"Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy","author":"Cunningham\u2010Rundles C","year":"1981"},{"key":"e_1_2_1_22_2","first-page":"431","volume-title":"Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy","author":"Thompson RA","year":"1981"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)91738-5"},{"key":"e_1_2_1_24_2","first-page":"223","volume-title":"Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy","author":"Barandun S","year":"1981"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198508293130914"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90316-4"},{"issue":"284","key":"e_1_2_1_27_2","first-page":"49","article-title":"Evidence of persistent IgA\/IgG circulating immune complexes associated with activation of the complement system in serum of a patient with common variable immune deficiency: anaphylactic reactions to intravenous gammaglobulin","volume":"92","author":"Wahn V","year":"1984","journal-title":"Acta Pathol Microbiol Immunol Scand"},{"key":"e_1_2_1_28_2","volume-title":"Gammagard product literature","author":"Hyland Therapeutics Division, Travenol Laboratories, Inc.","year":"1986"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1987.tb03510.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1987.tb03510.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1987.tb03510.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:49:25Z","timestamp":1761065365000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1987.tb03510.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,3,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1987,3,4]]}},"alternative-id":["10.1002\/j.1875-9114.1987.tb03510.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1987.tb03510.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,3,4]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}